Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Down 16.9% in April

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 2,070,000 shares, a decrease of 16.9% from the March 31st total of 2,490,000 shares. Based on an average daily volume of 2,290,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 3.8% of the shares of the company are sold short.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Large investors have recently modified their holdings of the business. Swiss National Bank boosted its holdings in Vanda Pharmaceuticals by 3.4% in the 3rd quarter. Swiss National Bank now owns 126,300 shares of the biopharmaceutical company’s stock worth $546,000 after buying an additional 4,100 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Vanda Pharmaceuticals by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 5,186 shares in the last quarter. Public Employees Retirement System of Ohio boosted its holdings in shares of Vanda Pharmaceuticals by 13.7% in the third quarter. Public Employees Retirement System of Ohio now owns 75,648 shares of the biopharmaceutical company’s stock worth $327,000 after acquiring an additional 9,100 shares during the period. Trexquant Investment LP grew its position in shares of Vanda Pharmaceuticals by 2,154.6% in the third quarter. Trexquant Investment LP now owns 274,252 shares of the biopharmaceutical company’s stock valued at $1,185,000 after purchasing an additional 262,088 shares in the last quarter. Finally, Caxton Associates LP raised its stake in shares of Vanda Pharmaceuticals by 364.3% during the 3rd quarter. Caxton Associates LP now owns 192,884 shares of the biopharmaceutical company’s stock valued at $833,000 after purchasing an additional 151,344 shares during the period. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Trading Up 4.3 %

Shares of NASDAQ VNDA opened at $4.82 on Tuesday. The firm has a market cap of $277.34 million, a price-to-earnings ratio of 96.42 and a beta of 0.76. The stock has a fifty day simple moving average of $4.28 and a two-hundred day simple moving average of $4.07. Vanda Pharmaceuticals has a 1-year low of $3.30 and a 1-year high of $7.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05. Vanda Pharmaceuticals had a return on equity of 0.46% and a net margin of 1.30%. The company had revenue of $45.27 million during the quarter, compared to the consensus estimate of $37.00 million. Analysts forecast that Vanda Pharmaceuticals will post -0.06 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. TheStreet cut Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research note on Thursday, February 8th. StockNews.com cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, April 22nd.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.